Skip To Main Content
Stanton R. Mehr on Muck Rack

Stanton R. Mehr

Philadelphia
As seen in: Biosimilars Review & Report, Pharmaceutical Medicine, American Journal of Managed Care, OncLive, Pharmaceutical Executive, Life Science Leader, Bioprocess Online, Biosimilar Development
For 30 years, Stan has been writing, editing, and presenting on a variety of health care topics, including biosimilars through his company and BR&R website.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stanton R.

Contact Stanton R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Are Biosimilar Patient Copay Assistance Programs Lacking?

|
By Stanton R. Mehr
| Biosimilars Review & Report
Our survey found that 87% of biosimilar products were associated with patient copay assistance programs that cut out-of-pocket costs to $5 or less. Physician perceptions of important financial assistance differences between biosimilars and reference products seem generally unfounded.
Open in Who Shared Issue with article?

Trump Tariffs on Generics and Biosimilars: Utter Nonsense or Just Plain Stupidity?

|
By Stanton R. Mehr
| Biosimilars Review & Report
Trump’s desire to remove a drug tariff exemption for generics and biosimilars produced overseas is ill-conceived and truly damaging to these low-margin industries. The Trump administration seems to think that making generics and biosimilars more expensive to the health system and consumers alike is a great idea.
Open in Who Shared Issue with article?

Tracking Two Bills to Remove the Clinical Efficacy Study Requirement for Biosimilar Development

|
By Stanton R. Mehr
| Biosimilars Review & Report
Proposals in the House and Senate, both titled the Expedited Access to Biosimilars Act, may officially remove the FDA’s requirement for clinical efficacy studies for biosimilar candidates. On July 15th, a new bipartisan bill was introduced into the House of Representatives that would expand access to biosimilars by modernizing the FDA’s biosimilar approval process. This could be paired with a similar proposal just reaching Senate Committee discussion.
Open in Who Shared Issue with article?
See all 262 licensed articles (267 Total)